Peptic Ulcer Drugs Market size was valued at USD 4.1  billion in 2021, growing at a significant CAGR of 2.1% from 2022-28. Peptic ulcer drugs market report gives a comprehensive outlook across the globe with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa. The report on global gives historical, current, and future market sizes (US$ Mn) on the basis of product type, formulation, application, distribution channel, and regions. This report studies global dynamics elaborately to identify the current market trends and drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, global report includes competition analysis with vividly illustrated competition dashboard to assess the market competition. Moreover, PBI analyzed the global Peptic ulcer drugs market to better equip clients with possible investment opportunities across the regions and market unmet needs (Product Opportunities). Key stakeholders of the global report include suppliers, manufacturers, marketers, policy makers, and agronomists engaged in global activities. low profile additives market is consolidating as large players complementing each other’s businesses by means of collaborations, agreements and acquisitions. Peptic ulcers are used in the treatment of certain types of gastrointestinal disorders that include gastric ulcers, gastritis, and duodenal ulcers or gastroesophagal reflux disease (GERD). These drugs minimize the amount of acid produced by the stomach. The most common symptoms associated with peptic ulcer include abdominal pain, vomiting, belching, poor appetite, and weight loss. Peptic ulcers can be treated by using various drugs such as proton pumps inhibitors (PPIs), H2 receptor antagonists, antacids, and antibiotics among others In February 2018, Strides Shasun decided to launch the Ranitidine 150 mg over the counter drug in U.S. for the treatment of peptic ulcers